



FOR IMMEDIATE RELEASE:

EYEGATE PHARMA TO PRESENT AT BIO INVESTORFORUM 2007

Waltham, MA – September 25, 2007 – EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced that Stephen From, President and Chief Executive Officer, will present at BIO InvestorForum 2007 at the Palace Hotel in San Francisco, CA, from October 9-11, 2007. Mr. From will present on Wednesday, October 10 at 3:45 PM in the Napa conference room. He will be available for one-on-one meetings during the conference.

BIO InvestorForum 2007 will feature corporate presentations and dynamic panel discussions on the opportunities and challenges facing the industry. The program includes public and venture-stage company presentations, expert-led workshops on the latest market and investment opportunities with an emphasis on drug and technology development. There will also be one-on-one investor meetings and breakout sessions between presenting company executives and investors. In attendance will be institutional investors, hedge fund managers, venture and private equity investors, as well as research analysts and bankers representing leading banking institutions. For more information please visit

<http://investorforum.bio.org/opencms/bif/2007/index.jsp>

About EyeGate Pharma

EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate[®] II Delivery System, was designed by ophthalmologists for ophthalmologists. This non-invasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies utilizing the EyeGate[®] II Delivery System are scheduled to begin in 2008. For more information please visit www.eyegatepharma.com

#

Contact:

Tim Allison
LaVoie Group
978-745-4200 X102
tallison@lavoiegroup.com